A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Front Oncol · 2020 · PMC7069552 · PMID 32211333

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

In brief, the heterogeneity of patients changing from the 4/2 to the 2/1 schedule may be significant, so we believed that it was inappropriate if we included these patients as intervention or control groups.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.